Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02079181 · ClinicalTrials.gov registry record · NA

18F-FMAU PET/CT in Imaging Patients With Advanced Cancers

A NA study, sponsored by University of Southern California.

Terminated
Registry status
NA
Development phase
3
Enrollment target

NCT02079181 is a NA study that was terminated before completion, run by University of Southern California. The registered enrollment target is 3 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02079181, a NA study, was terminated before completion, sponsored by University of Southern California.

TERMINATED
Registry status
NA
Development phase
3 participants
Enrollment target

Study Summary

This clinical trial studies the safety and drug distribution of the radioactive drug, 2'-deoxy-2'-\[18F\]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (fluorine F 18 d-FMAU \[18F-FMAU\]), for imaging with positron emission tomography/computed tomography (PET/CT) in patients with advanced cancers. A PET scan is a procedure in which a small amount of radioactive glucose (sugar) is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where the glucose is taken up. Because cancer cells often take up more glucose than normal cells, the pictures can be used to find cancer cells in the body. PET/CT using the drug fluorine F 18 d-FMAU, may help find cancer and find out how far the disease has spread.

Interventions

  • PROCEDURE positron emission tomography
  • PROCEDURE computed tomography
  • RADIATION fluorine F 18 d-FMAU

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2014-01-31
Est. Completion 2023-08-22
Phase NA

Sponsor

University of Southern California

617 total trials

What the Registry Record Tells You About NCT02079181

The ClinicalTrials.gov registry entry for NCT02079181 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which positron emission tomography is the first listed.

NCT02079181 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02079181 about?

NCT02079181 is a clinical study titled "18F-FMAU PET/CT in Imaging Patients With Advanced Cancers". This clinical trial studies the safety and drug distribution of the radioactive drug, 2'-deoxy-2'-\[18F\]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (fluorine F 18 d-FMAU \[18F-FMAU\]), for imaging with positron emission tomography/computed tomography (PET/CT) in patients with advanced cancers. ...

What is the current status of trial NCT02079181?

This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2014-01-31. Estimated completion is 2023-08-22.

What interventions are being tested in trial NCT02079181?

The interventions under investigation include: positron emission tomography (PROCEDURE), computed tomography (PROCEDURE), fluorine F 18 d-FMAU (RADIATION).

Who is sponsoring clinical trial NCT02079181?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.